Zebinix is an epilepsy medicine used to treat adults with partial-onset seizures (epileptic fits) with or without secondary generalisation. This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness or a sudden sense of fear. Secondary generalisation occurs when the overactivity later reaches the whole brain. Zebinix can be taken on its own, in newly diagnosed epilepsy, or can be added to existing antiepileptic medicines. Zebinix can also be used in adolescents and children above 6 years of age, in combination with existing therapies, to treat partial-onset seizures with or without secondary generalisation. Zebinix contains the active substance eslicarbazepine acetate.
Therapeutic Indication
### Therapeutic indication Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.
Therapeutic Area (MeSH)
ATC Code
N03AF04
ATC Item
eslicarbazepine
Pharmacotherapeutic Group
Antiepileptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| eslicarbazepine acetate | N/A | 醋酸艾司利卡西平 |
EMA Name
Zebinix
Medicine Name
Zebinix
Aliases
N/ANo risk management plan link.